Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA). The license expands Trethera’s intellectual property (IP) estate for TRE-515, its lead deoxycytidine kinase (dCK) inhibitor, to include new therapeutic uses in autoimmune and inflammatory diseases.

The new license, which includes both method of use claims and compound structures, significantly extends Trethera’s patent protection in the world’s largest pharmaceutical markets. When combined with existing granted patents and filings, the new IP asset potentially secures market exclusivity for TRE-515 through at least February 2045 – supporting a long-term commercial strategy.

“This newly licensed intellectual property fortifies our already robust patent estate,” said Dr. Ken Schultz, Chairman and CEO of Trethera. “Alongside our existing composition of matter patent and ongoing proprietary discovery work, we have created a durable patent strategy to protect and maximize the full clinical and commercial value of TRE-515 across multiple therapeutic indications.”

TRE-515 is currently in Phase 1 clinical trials for cancer, an expanded clinical access program for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease), and preclinical research demonstrating promising activity in multiple autoimmune and inflammatory diseases. Trethera’s expanding IP portfolio includes multiple granted U.S. and international patents, and pending applications covering both composition and method of use claims across oncology and immunology.